Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biological chemistry

• Publication date

  2010-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1515/bc.2010.037PMID 20180638
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclosporin

  2012cited by this paper
• In vivo biosynthesis of an Ala-scan library based on the cyclic peptide SFTI-1

  2010cited by this paper
• R&D Paradigm Shift and Billion‐Dollar Biologics

  2010cited by this paper
• Preparation of some 2-phenylisopropyl-oxycarbonyl amino acids. Evaluation of their properties with particular reference to application in solid phase peptide synthesis.

  2009cited by this paper
• SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor.

  2009cited by this paper
• Identification of Lympho-Epithelial Kazal-Type Inhibitor 2 in Human Skin as a Kallikrein-Related Peptidase 5-Specific Protease Inhibitor

  2009cited by this paper
• Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases.

  2009cited by this paper
• A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition.

  2009cited by this paper
• Lessons Learned in Antifibrinolytic Therapy: The BART Trial

  2009cited by this paper
• Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome

  2009cited by this paper
• Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspective

  2009cited by this paper
• Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.

  2009cited by this paper
• Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases.

  2008cited by this paper
• Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display

  2008cited by this paper
• Distribution and Evolution of Circular Miniproteins in Flowering Plants[W]

  2008cited by this paper
• Substrate specificity of human kallikreins 1 and 6 determined by phage display

  2008cited by this paper
• Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration

  2008cited by this paper
• Novel small molecule inhibitors for prostate‐specific antigen

  2008cited by this paper
• Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids

  2008cited by this paper
• Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?

  2008cited by this paper
• Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade

  2008cited by this paper
• Modulation of antibody pharmacokinetics by chemical polysialylation.

  2008cited by this paper
• Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues.

  2008cited by this paper
• Discovering and improving novel peptide therapeutics.

  2008cited by this paper
• Development of peptides specifically modulating the activity of KLK2 and KLK3

  2008cited by this paper
• Prostate-Specific Kallikreins-2 and -4 Enhance the Proliferation of DU-145 Prostate Cancer Cells through Protease-Activated Receptors-1 and -2

  2008cited by this paper
• Neuropsin (KLK8)-Dependent and -Independent Synaptic Tagging in the Schaffer-Collateral Pathway of Mouse Hippocampus

  2008cited by this paper
• Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.

  2008cited by this paper
• D‐SAP: A New, Noncytotoxic, and Fully Protease Resistant Cell‐Penetrating Peptide

  2008cited by this paper
• Genetic features of circular bacteriocins produced by Gram-positive bacteria.

  2008cited by this paper
• Peptide and protein PEGylation III: advances in chemistry and clinical applications☆

  2008cited by this paper
• Chymotryptic specificity determinants in the 1.0 Å structure of the zinc-inhibited human tissue kallikrein 7

  2007cited by this paper
• Defining the extended substrate specificity of kallikrein 1-related peptidases

  2007cited by this paper
• SerpinB6 is an inhibitor of kallikrein-8 in keratinocytes.

  2007cited by this paper
• Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.

  2007cited by this paper
• Kallikrein 8 Is Involved in Skin Desquamation in Cooperation with Other Kallikreins*

  2007cited by this paper
• Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea

  2007cited by this paper
• Activity and stability of human kallikrein‐2‐specific linear and cyclic peptide inhibitors

  2007cited by this paper
• Enzymatic properties of human kallikrein-related peptidase 12 (KLK12)

  2007cited by this paper
• Delivery methods for peptide and protein toxins in insect control.

  2007cited by this paper
• Structural basis of the zinc inhibition of human tissue kallikrein 5.

  2007cited by this paper
• Expression and Functional Characterization of the Cancer-related Serine Protease, Human Tissue Kallikrein 14*

  2007cited by this paper
• Activation and enzymatic characterization of recombinant human kallikrein 8

  2006cited by this paper
• Human Tissue Kallikrein 5 Is a Member of a Proteolytic Cascade Pathway Involved in Seminal Clot Liquefaction and Potentially in Prostate Cancer Progression*

  2006cited by this paper
• Human kallikrein 10, a predictive marker for breast cancer

  2006cited by this paper
• Specificity Profiling of Seven Human Tissue Kallikreins Reveals Individual Subsite Preferences*

  2006cited by this paper
• Targeting proteases: successes, failures and future prospects

  2006cited by this paper
• Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum

  2006cited by this paper
• Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells

  2006cited by this paper
• Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site.

  2006cited by this paper
• Overcoming HIV-1 resistance to protease inhibitors

  2006cited by this paper
• Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14

  2006cited by this paper
• Rapid kinetic-based screening of human Fab fragments.

  2006cited by this paper
• Novel Peptide Inhibitors of Human Kallikrein 2*

  2006cited by this paper
• Protease inhibitors and their peptidomimetic derivatives as potential drugs

  2006cited by this paper
• Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long‐term potentiation in adult mouse hippocampus in vivo

  2006cited by this paper
• Strategies to improve plasma half life time of peptide and protein drugs

  2006cited by this paper
• Inhibition profiles of human tissue kallikreins by serine protease inhibitors

  2006cited by this paper
• What is Hidden Behind Peptide Bond Restriction and α-Carbon Asymmetry of Conserved Antigens? Peptide Bond Isosters and Chirally Transformed Pseudopeptides as Novel Elements for Synthetic Vaccines and Therapeutic Agents Against Malaria

  2006cited by this paper
• A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation*

  2006cited by this paper
• Optimized selective N‐methylation of peptides on solid support

  2006cited by this paper
• Differential expression of protease M/neurosin in oligodendrocytes and their progenitors in an animal model of multiple sclerosis.

  2005cited by this paper
• hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6

  2005cited by this paper
• T cell determinants incorporating beta-amino acid residues are protease resistant and remain immunogenic in vivo.

  2005cited by this paper
• Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.

  2005cited by this paper
• Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI)

  2005cited by this paper
• A proteolytic cascade of kallikreins in the stratum corneum.

  2005cited by this paper
• Substrates of the prostate‐specific serine protease prostase/KLK4 defined by positional‐scanning peptide libraries

  2005cited by this paper
• Plant serine proteinase inhibitors.

  2005cited by this paper
• Disulfide bond mutagenesis and the structure and function of the head-to-tail macrocyclic trypsin inhibitor SFTI-1.

  2005cited by this paper
• The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis.

  2005cited by this paper
• Proteases universally recognize beta strands in their active sites.

  2005cited by this paper
• Enzymatic profiling of human kallikrein 14 using phage-display substrate technology

  2005cited by this paper
• Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins

  2005cited by this paper
• Adaptive inhibitors of the HIV-1 protease.

  2005cited by this paper
• Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII.

  2005cited by this paper
• Recent progress of the synthetic studies of biologically active marine cyclic peptides and depsipeptides.

  2005cited by this paper
• In-silico analysis of kallikrein gene expression in pancreatic and colon cancers.

  2004cited by this paper
• Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates.

  2004cited by this paper
• Limitations of the Coupling of Amino Acid Mixtures for the Preparation of Equimolar Peptide Libraries

  2004cited by this paper
• Human kallikrein 13 involvement in extracellular matrix degradation.

  2004cited by this paper
• The periplasmic serine protease inhibitor ecotin protects bacteria against neutrophil elastase.

  2004cited by this paper
• The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers

  2004cited by this paper
• Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.

  2004cited by this paper
• The emerging roles of human tissue kallikreins in cancer

  2004cited by this paper
• Targeting kallikrein 6‐proteolysis attenuates CNS inflammatory disease

  2004cited by this paper
• A proteinase inhibitor from Caesalpinia echinata (pau-brasil) seeds for plasma kallikrein, plasmin and factor XIIa

  2004cited by this paper
• Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7.

  2004cited by this paper
• Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression.

  2004cited by this paper
• Parallel overexpression of seven kallikrein genes in ovarian cancer.

  2003cited by this paper
• Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies.

  2003cited by this paper
• Engineering of a macromolecular scaffold to develop specific protease inhibitors

  2003cited by this paper
• Human and mouse proteases: a comparative genomic approach

  2003cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.

  2003cited by this paper
• Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues

  2003cited by this paper
• DX-88 and HAE: a developmental perspective.

  2003cited by this paper
• Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.

  2002cited by this paper
• Activity of a newly identified serine protease in CNS demyelination.

  2002cited by this paper
• Chemical synthesis and kinetic study of the smallest naturally occurring trypsin inhibitor SFTI-1 isolated from sunflower seeds and its analogues.

  2002cited by this paper

• Drug Discovery Strategies for Kallikrein-Related Peptidases

  2025cites this paper
• Insights into platypus crural gland transcriptomics – venom and beyond

  2025cites this paper
• Kallikrein immobilized on magnetic beads for activity-based assays using mass spectrometry

  2025cites this paper
• Targeting kallikrein proteases for dandruff therapy.

  2024cites this paper
• The roles of proteases in prostate cancer

  2023cites this paper
• Plant-Derived Compounds and Extracts as Modulators of Plasmin Activity—A Review

  2023cites this paper
• The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets

  2020cites this paper
• Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif

  2019cites this paper
• Roles of Kallikrein-Related Peptidase in Epidermal Barrier Function and Related Skin Diseases

  2019cites this paper
• A Versatile and Robust Serine Protease Inhibitor Scaffold from Actinia tenebrosa

  2019cites this paper
• Surface loops of trypsin-like serine proteases as determinants of function.

  2019cites this paper
• Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses

  2019cites this paper
• A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering

  2018influential citation
• Cyclic Peptide Serine Protease Inhibitors Based on the Natural Product SFTI‐1

  2018cites this paper
• Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency

  2018cites this paper
• Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.

  2018cites this paper
• Inhibitors of kallikrein‐related peptidases: An overview

  2018cites this paper
• Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.

  2017cites this paper
• Toward a Universal Method for Preparing Molecularly Imprinted Polymer Nanoparticles with Antibody-like Affinity for Proteins.

  2016cites this paper
• Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies

  2016cites this paper
• The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.

  2016cites this paper
• Risk management for point-of-care testing

  2015cites this paper
• Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges

  2015influential citation
• Unleashing the therapeutic potential of human kallikrein-related serine proteases

  2015cites this paper
• KLK-targeted Therapies for Prostate Cancer

  2014influential citation
• Risk Management for Point-of-Care Testing

  2014cites this paper
• Cystine-knot peptides: emerging tools for cancer imaging and therapy

  2014cites this paper
• Targeting kallikrein-related peptidases in prostate cancer

  2014influential citation
• The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine The Journal of the International Federation of Clinic l Chemistry and Laboratory Medicine Communications and Publications Division ( CPD ) of the IFCC

  2014cites this paper
• Antiangiogenic and proteolytic activities of prostate-specific antigen

  2014cites this paper
• Proteomic and other analyses to determine the functional consequences of deregulated kallikrein‐related peptidase (KLK) expression in prostate and ovarian cancer

  2014cites this paper
• Metastasis of ovarian cancer is mediated by kallikrein related peptidases

  2013cites this paper
• Regulation of kallikrein-related peptidases in the skin – from physiology to diseases to therapeutic options

  2013cites this paper
• Mechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1.

  2013cites this paper
• Proteolytic activation of prochemerin by kallikrein 7 breaks an ionic linkage and results in C-terminal rearrangement.

  2013cites this paper
• Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14

  2012cites this paper
• Natural and Engineered Plasmin Inhibitors: Applications and Design Strategies

  2012cites this paper
• Synthesis of an erodible biomimetic hydrogel for drug delivery using native chemical ligation

  2012cites this paper
• Selective cleavage of human sex hormone-binding globulin by kallikrein-related peptidases and effects on androgen action in LNCaP prostate cancer cells.

  2012cites this paper
• Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development.

  2012cites this paper
• Highlight: the 4th International Symposium on Kallikreins and Kallikrein-related peptidases.

  2012cites this paper
• Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors.

  2011cites this paper
• Mastering the Canonical Loop of Serine Protease Inhibitors: Enhancing Potency by Optimising the Internal Hydrogen Bond Network

  2011cites this paper
• The 3(rd) International Symposium on Kallikreins and Kallikrein-Related Peptidases.

  2010cites this paper
• Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs)

  2010cites this paper